Precision oncology company Guardant Health Inc (Nasdaq:GH) announced on Thursday that the US Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertinib tablets), a targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option.
This approval enables the liquid biopsy test to identify patients eligible for treatment by detecting HER2 (ERBB2) tyrosine kinase domain activating mutations from circulating tumour DNA in a blood sample.
HERNEXEOS is indicated for adult patients with unresectable or metastatic non-squamous NSCLC with HER2 mutations as detected by an FDA-authorised test, under accelerated approval based on response metrics.
Guardant360 CDx, the first FDA-approved liquid biopsy for comprehensive genomic profiling across multiple tumour types, supports treatment matching and clinical trial identification. This approval marks the 27th companion diagnostic indication for the platform globally.
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
Lupin's Ranluspec (ranibizumab) injection receives US FDA approval
Pharming secures FDA acceptance of Joenja filing for children with APDS
Medtronic seeks expanded US approvals for Hugo robotic surgery system
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection
Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan
FDA accepts Genentech's giredestrant application for early-stage breast cancer
Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC